Sign up
Log in
Ambarella Full Year 2025 Earnings: Beats Expectations
Share
Listen to the news

Ambarella (NASDAQ:AMBA) Full Year 2025 Results

Key Financial Results

  • Revenue: US$284.9m (up 26% from FY 2024).
  • Net loss: US$117.1m (loss narrowed by 31% from FY 2024).
  • US$2.84 loss per share (improved from US$4.25 loss in FY 2024).
revenue-and-expenses-breakdown
NasdaqGS:AMBA Revenue and Expenses Breakdown March 31st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ambarella Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 7.1%.

The primary driver behind last 12 months revenue was the Taiwan segment contributing a total revenue of US$179.3m (63% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$226.1m (76% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$9.47m. Explore how AMBA's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Semiconductor industry in the US.

Performance of the American Semiconductor industry.

The company's shares are down 9.0% from a week ago.

Risk Analysis

We should say that we've discovered 2 warning signs for Ambarella that you should be aware of before investing here.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.